Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology

Comment

Sam S Chang. J Urol. 2023 Jun.

. 2023 Jun;209(6):1228-1229.

doi: 10.1097/JU.0000000000003411. Epub 2023 Mar 23.

No abstract available

Comment on

Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
Pederzoli F, Bandini M, Raggi D, Marandino L, Basile G, Alfano M, Colombo R, Salonia A, Briganti A, Gallina A, Montorsi F, Necchi A. Pederzoli F, et al. Eur Urol. 2021 Sep;80(3):319-322. doi: 10.1016/j.eururo.2021.05.018. Epub 2021 May 27. Eur Urol. 2021. PMID: 34053782 Clinical Trial.
First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.
Meghani K, Cooley LF, Choy B, Kocherginsky M, Swaminathan S, Munir SS, Svatek RS, Kuzel T, Meeks JJ. Meghani K, et al. Eur Urol. 2022 Dec;82(6):602-610. doi: 10.1016/j.eururo.2022.08.004. Epub 2022 Aug 23. Eur Urol. 2022. PMID: 36008193 Free PMC article.
DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Lindgren MS, Hansen E, Azawi N, Nielsen AM, Dyrskjøt L, Jensen JB. Lindgren MS, et al. J Clin Oncol. 2023 Jan 10;41(2):206-211. doi: 10.1200/JCO.22.00470. Epub 2022 Oct 12. J Clin Oncol. 2023. PMID: 36223555 Clinical Trial.